The MyRealWorld Myasthenia Gravis Registry

The MyRealWorld™ MG study was a global, longitudinal, community‑recruited observational registry designed to capture the real‑world impact of myasthenia gravis (MG) on adults living with the condition. 

Running from 2019 to 2024, the registry collected extensive patient‑reported data across symptoms, treatment patterns, healthcare utilisation, and quality of life, providing one of the largest international real‑world MG datasets to date.

For those with MG

Share your voice. Shape MG research.


Learn More strelica

I am a clinician working in MG

Join clinicians building better MG evidence.


Learn More strelica

I am a researcher working in MG

Access insights to accelerate MG research.


Learn More strelica

Partnership with Patient Advocacy Groups Across 10 Countries

MyRealWorld™ MG was co‑created in close collaboration with patient advocacy groups (PAGs) and key opinion leaders (KOLs) across all ten participating countries. These partners contributed to:

  • Selecting variables that truly reflect the lived burden of MG
  • Ensuring cultural and clinical relevance across diverse health systems
  • Supporting patient engagement and retention
  • Representing the patient voice in registry governance

This multi‑country PAG partnership enabled a deeply patient‑centered design and ensured that the registry reflected the daily realities of MG across North America, Europe, and Asia.

Scientific Advisory Board 

The registry was governed by an independent, international Scientific Advisory Board (SAB) comprising leading MG clinicians, patient advocacy representation, and sponsor representatives. The SAB provided oversight of scientific rigor, participant interests, data access requests, and publication strategy.

About The VRMG Registry
Data Variables

The MyRealWorld™ MG registry captured a rich, granular dataset combining custom survey variables, highfrequency longitudinal trackers, and a wide suite of validated patient-reported outcome (PRO) instruments. 

Across ten countries, the registry collected detailed information on demographics, MG subtype, diagnostic pathway, antibody status, MGFA class, thymus involvement, comorbidities, lifetime and recent treatment history, rescue therapy use, sideeffects, treatment satisfaction, healthcare utilisation, exacerbations, work and productivity impact, living situation, and caregiver burden. Monthly trackers added further depth by capturing treatment changes, symptom burden, healthcare visits, and time costs. 

This was complemented by a uniquely comprehensive PRO set, including EQ-5D-5L (with MG-relevant bolt-ons), MG-ADL, MG-QoL15r, HADS, HUI-3, PROMIS measures, and FACIT Fatigue. This enabled a multi-dimensional, longitudinal view of real-world MG burden and quality of life with exceptional granularity.

A Unique MG dataset 

Digital Patient Registry
Built with and for
Community Impact
RWE
PRO dataset

Built with, not just for, the MG community

The registry was co developed with PAGs and clinicians in each country, ensuring relevance to real world clinical practice and patient needs.

One of the largest international MG Patient-Reported Outcome datasets
With ~2,100 participants across 10 countries, it captured wide variation in disease experiences, healthcare systems, and treatment pathways.

Rich, granular data on real-world MG

The dataset included:

• Demographics and diagnostic journey
• MGFA class, antibody status, thymus involvement
• Detailed treatment pathways (lifetime + 12 month windows)
• Rescue therapies
• Side effects and treatment satisfaction
• Exacerbations and healthcare utilisation
• Living situation, caregiver burden, and work/study impact

High frequency symptom and treatment tracking

Monthly tracker surveys captured changes in treatment, symptoms, work productivity, and healthcare visits — enabling longitudinal insight into how MG evolves and impacts daily life.

A global perspective on MG

By spanning 10 countries, MyRealWorld™ MG produced internationally comparable insights reflecting real differences in care, treatment access, and disease burden.

COVID-19 add-on module during 2020-2021

A bespoke PRO instrument captured the pandemic’s specific impact on people with MG, later removed when no longer needed.

Flexible data capture

Modular setup supports different study designs, sites, and country-level requirements while keeping a consistent participant experience.

Our Publications

Get Involved

Whether you’re exploring a research collaboration, real-world evidence generation, or feasibility for a future study, we’d love to hear from you.

Submit your enquiry below and our team will follow up to discuss how our Myasthenia Gravis registry can support your research goals. Academic researchers can also request information on the MGFA RFP, including a $10,000 award to support studies leveraging this dataset.

    Contact the MRWMG Registry Team

    1) Your details







    2) Enquiry type (select all that apply)

    What would you like to discuss? (select all that apply)


    3) Academic grant

    Are you interested in the MGFA RFP funding opportunity?

    (Available to academic researchers - $10,000 award)

    4) Message


    0/500

    5) Compliance

    We’ll use your details to respond to your enquiry. We may also contact you with relevant updates from Vitaccess.
    You can unsubscribe at any time. See our Privacy Policy for details.

    See Our FAQ Join the Registry Skip to content